Christopher Benecchi - Apr 10, 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Operating Officer
Signature
Brandon Marsh, attorney in fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Apr 10, 2025
Transactions value $
-$10,047
Form type
4
Date filed
4/11/2025, 04:09 PM
Previous filing
Feb 14, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +3.26K +7.41% $0.00 47.2K Apr 10, 2025 Direct F1
transaction SAGE Common Stock Tax liability -$5.48K -793 -1.68% $6.91 46.4K Apr 10, 2025 Direct
transaction SAGE Common Stock Award $0 +2.71K +5.85% $0.00 49.1K Apr 10, 2025 Direct F2
transaction SAGE Common Stock Tax liability -$4.57K -661 -1.35% $6.91 48.4K Apr 10, 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 9,300 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 3,255 shares.
F2 On June 16, 2022, the reporting person was granted PSUs to acquire a total of 7,750 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 2,712 shares.